Related Experiment Video
Updated: Aug 13, 2026

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture
Published on: December 22, 2016
Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12
Alec Aeby1, Nathalie Poznanski, Denis Verheulpen
1Department of Pediatric Neurology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium. alec.aeby@ulb.ac.be
Insights
Levetiracetam showed positive effects on EEG, behavior, and cognition in children with continuous spikes and waves during slow sleep (CSWS). Further research is needed to confirm its role in treating this epilepsy syndrome.
Area of Science:
- Pediatric Neurology
- Epileptology
- Clinical Neurophysiology
Background:
- Continuous spikes and waves during slow sleep (CSWS) is an epilepsy syndrome associated with significant behavioral and cognitive deterioration in children.
- Identifying effective add-on treatments for CSWS is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the add-on efficacy of levetiracetam in children diagnosed with CSWS.
- To assess levetiracetam's impact on electroencephalogram (EEG) patterns, behavior, and cognitive function.
Main Methods:
- Retrospective chart review of children with CSWS treated with levetiracetam (50 mg/kg/day).
- Analysis of EEG recordings and neuropsychological/behavioral assessments at baseline and 2 months post-treatment.
- Long-term follow-up at 1 year for patients showing initial improvement.
Main Results:
- Of 12 patients, 7 (58.3%) demonstrated EEG improvement; 3 of these showed neuropsychological gains, and 4 showed behavioral improvement.
- Two patients improved neuropsychologically despite no EEG changes.
- 8 patients (66.6%) continued levetiracetam beyond 2 months, with 4 remaining on it at 1 year due to sustained benefits.
Conclusions:
- Levetiracetam appears to offer benefits for EEG, behavior, and cognition in pediatric patients with CSWS.
- Further prospective studies are required to establish levetiracetam's definitive role in managing CSWS.
Purpose:
To assess the add-on efficacy of levetiracetam on the EEG, behavior, and cognition of children with continuous spikes and waves during slow sleep (CSWS).
Methods:
Charts of children with behavioral and/or cognitive deterioration associated with CSWS who received levetiracetam at 50 mg/kg/day as add-on treatment were retrospectively reviewed. Awake and sleep EEG recordings and detailed neuropsychological and behavioral assessments were available at baseline and 2 months after levetiracetam initiation. In children showing clinical and/or electrophysiological improvement after 2 months, levetiracetam was continued with a new evaluation at 1 year.
Results:
Twelve patients were included (9 cryptogenic and 3 symptomatic cases). Seven patients (58.3%) showed improvement of EEG record. Among these seven patients, neuropsychological evaluation was improved in three, and in the other four patients, not testable because of severe cognitive impairment, behavior was improved. Two patients improved in neuropsychological evaluation despite the lack of EEG improvement. Eight patients (66.6%) continued levetiracetam treatment after 2 months. After 1 year, four patients were still on levetiracetam, two because sustained effect on EEG and behavior and the two others because improvement in neuropsychological testing despite unchanged EEG. Levetiracetam was discontinued in the other four patients because of neuropsychological or behavioral deterioration associated with CSWS pattern, between 9 and 11 months after treatment initiation.
Conclusions:
This retrospective study suggests that levetiracetam has a positive effect on the EEG, the behavior, and the cognition of patients with epilepsy and CSWS. Additional studies are warranted in order to assess the place of this drug in these epileptic conditions.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Electroconvulsive Therapy
Epilepsy ll: Types
Seizures l: Introduction

